COLL Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in November:

• The Jefferies London Healthcare Conference on Thursday, November 17th at 12:40 p.m. GMT at the Waldorf Hilton London Hotel
• The 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30th at 12:00 p.m. EST at the Lotte New York Palace Hotel

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  For Important Safety Information including full prescribing information visit: http://www.xtampzaer.com/.

Contact: 
Douglas Carlson
Vice President, Corporate Development
dcarlson@collegiumpharma.com